A newly funded study will test whether depression treatment can become substantially faster without sacrificing lasting benefit. In its September 30 announcement, NRx Defense Systems reported an approximately $11.2 million DARPA prime contract to evaluate single-day robotic transcranial magnetic stimulation combined with NRX-101.
The project, called Synaptic Plasticity Augmented Rapid Circuit Stimulation, or SPARC-TMS, targets a practical challenge: making treatment for resistant depression easier to deliver when repeated clinic visits are difficult.
Why Treatment Time Matters
TMS uses magnetic pulses to stimulate brain regions involved in mood regulation. Conventional treatment commonly involves repeated outpatient visits over several weeks, creating scheduling, transportation, and access barriers.
Those demands are particularly relevant in military operational settings, where continuity of care can be difficult. Shortening treatment could address an important logistical limitation, but a compressed schedule must still demonstrate acceptable safety, meaningful symptom improvement, and durability.
DARPA Depression Research Tests A Combined Approach
SPARC-TMS will investigate an entire TMS course delivered within one day alongside NRX-101, an investigational combination of D-cycloserine and lurasidone.
According to NRx, the program brings together McLean Hospital, Arizona State University, and HOPE Therapeutics, with plans to involve military hospitals. Robotic neuronavigation is intended to support consistent positioning of the stimulation coil.
The approach combines three elements: accelerated delivery, medication intended to influence treatment-related plasticity, and precise targeting. Evaluating that package requires evidence specific to the combined protocol.
The Trial Must Establish More Than Speed
The announcement describes an FDA-authorized investigation, rather than an approved depression treatment. Authorization to conduct a trial does not establish that NRX-101 combined with single-day TMS is effective.
A central question is whether concentrating stimulation into one day produces benefits that persist afterward. Symptom ratings, remission, adverse effects, and follow-up outcomes will therefore matter more than the number of clinic days alone.
Earlier Findings Provide A Rationale
NRx cites earlier work involving TMS and D-cycloserine, including real-world response and remission figures. These are background observations, not results from SPARC-TMS.
Separately, a randomized clinical trial published in JAMA Psychiatry studied 50 adults receiving intermittent theta-burst stimulation, a patterned form of TMS. Participants assigned adjunctive D-cycloserine experienced greater clinician-rated symptom improvement than those assigned placebo.
That study used a four-week treatment schedule and did not test NRX-101 or the proposed single-day robotic protocol. Its findings support further investigation of medication augmentation while leaving the new combination unproven. JAMA Network
The Biology Behind Medication Augmentation
The strategy centers on synaptic plasticity, the ability of connections between neurons to change. NMDA receptors participate in processes that help support these changes.
D-cycloserine acts as a partial agonist at NMDA receptors. NRx proposes that lurasidone may contribute through a complementary mechanism involving serotonin 5-HT7 receptor antagonism and NMDA receptor expression.
The hypothesis is that medication could make stimulation more therapeutically productive. Biological plausibility, however, cannot establish clinical benefit or predict how long an antidepressant response will last.
Robotic Precision Adds Another Research Dimension
Robotic neuronavigation aims to improve the consistency of stimulation placement. The company reports targeting precision of approximately one millimeter or less, although positioning accuracy should not be confused with demonstrated antidepressant effectiveness.
What distinguishes SPARC-TMS is the coordinated use of targeting technology, pharmacologic augmentation, and treatment compression. Determining which elements contribute to outcomes will depend on the study’s comparisons and eventual reporting.
A Funding Milestone With Clinical Questions Ahead
For clinics, a successful one-day protocol could reduce attendance burdens and change treatment scheduling. For patients and military health systems, its value would depend on accessibility, tolerability, sustained improvement, and any need for additional treatment.
NRx says the trial could potentially support a future regulatory submission. For now, the contract funds the evaluation of an ambitious treatment model. Its contribution to depression care will be determined by the clinical evidence it produces.
Citations
- NRx Defense Systems. September 30, 2026. DARPA contract announcement. NRx Defense Systems, an NRx Company (Nasdaq_NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression.pdf
- Cole J, et al. Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(12):1153–1161.
Explore more at https://www.interventionalpsychiatry.org/
